GlassScriptPhysician profile
Colleen Lindleaf
NPI 1417376781
$3,310.25
in general payments reported to CMS, 2019-2025
24 companies · $2,005 in 2025
The $2,005 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $37.92 · 2024: $1,267 · 2025: $2,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,310.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $532.47 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $506.86 | 2024-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $368.95 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $312.41 | 2024-2025 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $301.78 | 2024-2025 | |
| Glaxosmithkline, LLC. | $240.28 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $177.17 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $123.02 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $104.01 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $92.13 | 2024-2025 | |
| Exact Sciences Corporation | $82.87 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $76.94 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $66.72 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $62.41 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Scilex Pharmaceuticals INC. | $59.74 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.94 | 2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $30.23 | 2024 | Quviviq |
| Mayne Pharma Commercial LLC | $26.24 | 2025 | |
| Sumitomo Pharma America, INC. | $26.04 | 2025 | Gemtesa |
| Dexcom, INC. | $15.79 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $15.10 | 2025 | Nexletol |
| Vanda Pharmaceuticals INC. | $14.98 | 2024 | Fanapt, Hetlioz |
| Paratek Pharmaceuticals, INC. | $13.61 | 2024 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $13.56 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Lindleaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.